{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T21:23:47Z","timestamp":1778534627191,"version":"3.51.4"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01AI115520"],"award-info":[{"award-number":["U01AI115520"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Serological assays to detect antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might contribute to confirming the suspected coronavirus disease 2019 (COVID-19) in patients not detected with molecular assays. Human antibodies that target the host angiotensin-converting enzyme 2-binding domain of the viral spike protein are a target for serodiagnosis and therapeutics. This study aimed to characterize the classes and subclasses of antibody responses to a recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients and investigated the reactivity of these antibodies in patients with other tropical infections and healthy individuals in Thailand. ELISAs for IgM, IgA, IgG and IgG subclasses based on RBD antigen were developed and tested with time series of 27 serum samples from 15 patients with COVID-19 and 60 samples from pre-COVID-19 outbreaks including acute dengue fever, murine typhus, influenza, leptospirosis and healthy individuals. Both RBD-specific IgA and IgG were detected in only 21% of the COVID-19 patients in the acute phase. The median IgA and IgG levels were significantly higher in the convalescent serum sample compared to the acute serum sample (<jats:italic>P<\/jats:italic> &lt; 0.05). We observed the highest correlation between levels of IgG and IgA (rho = 0. 92). IgG1 and IgG3 were the major IgG subclasses detected in SARS-CoV-2 infection. Only acute IgG3 level was negatively associated with viral detection based on RT-PCR of <jats:italic>ORF1ab<\/jats:italic> gene (rho = -0.57). The median IgA and IgG levels in convalescence sera of COVID-19 patients were significantly higher than healthy individuals and convalescent sera of other febrile infectious patients. The analyses of antibody classes and subclasses provide insights into human immune responses against SARS-CoV-2 during natural infection and interpretation of antibody assays.<\/jats:p>","DOI":"10.1371\/journal.pone.0255796","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:34:14Z","timestamp":1628616854000},"page":"e0255796","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients in Thailand"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0261-3233","authenticated-orcid":true,"given":"Sarunporn","family":"Tandhavanant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2789-8060","authenticated-orcid":true,"given":"Sirikamon","family":"Koosakunirand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taniya","family":"Kaewarpai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Watcharapong","family":"Piyaphanee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pornsawan","family":"Leaungwutiwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-3720","authenticated-orcid":true,"given":"Viravarn","family":"Luvira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3906-7379","authenticated-orcid":true,"given":"Narisara","family":"Chantratita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,8,10]]},"reference":[{"issue":"6","key":"pone.0255796.ref001","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.arcmed.2020.05.012","article-title":"Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2","volume":"51","author":"S Satarker","year":"2020","journal-title":"Arch Med Res"},{"issue":"9","key":"pone.0255796.ref002","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","article-title":"Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19","volume":"41","author":"Y Huang","year":"2020","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"pone.0255796.ref003","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"181","author":"AC Walls","year":"2020","journal-title":"Cell"},{"issue":"15","key":"pone.0255796.ref004","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1016\/j.vaccine.2006.10.031","article-title":"Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model","volume":"25","author":"L Du","year":"2007","journal-title":"Vaccine"},{"issue":"1","key":"pone.0255796.ref005","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcv.2004.09.024","article-title":"Development and evaluation of an enzyme-linked immunosorbent assay for detection of antibodies against the spike protein of SARS-coronavirus","volume":"33","author":"J Zhao","year":"2005","journal-title":"J Clin Virol"},{"issue":"2","key":"pone.0255796.ref006","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.virol.2006.09.022","article-title":"A study on antigenicity and receptor-binding ability of fragment 450\u2013650 of the spike protein of SARS coronavirus","volume":"359","author":"J Zhao","year":"2007","journal-title":"Virology"},{"key":"pone.0255796.ref007","article-title":"COVID-19-neutralizing antibodies predict disease severity and survival","author":"WF Garcia-Beltran","year":"2020","journal-title":"Cell"},{"issue":"7","key":"pone.0255796.ref008","doi-asserted-by":"crossref","first-page":"100126","DOI":"10.1016\/j.xcrm.2020.100126","article-title":"Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike","volume":"1","author":"J Prevost","year":"2020","journal-title":"Cell Rep Med"},{"issue":"7","key":"pone.0255796.ref009","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3201\/eid2607.200841","article-title":"Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients","volume":"26","author":"NMA Okba","year":"2020","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"pone.0255796.ref010","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","volume":"17","author":"W Tai","year":"2020","journal-title":"Cell Mol Immunol"},{"issue":"7839","key":"pone.0255796.ref011","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","article-title":"SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies","volume":"588","author":"CO Barnes","year":"2020","journal-title":"Nature"},{"issue":"47","key":"pone.0255796.ref012","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1016\/j.vaccine.2020.09.061","article-title":"Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement","volume":"38","author":"WH Chen","year":"2020","journal-title":"Vaccine"},{"issue":"7830","key":"pone.0255796.ref013","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","article-title":"A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity","volume":"586","author":"J Yang","year":"2020","journal-title":"Nature"},{"key":"pone.0255796.ref014","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jpeds.2020.08.037","article-title":"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses","volume":"227","author":"LM Yonker","year":"2020","journal-title":"J Pediatr"},{"issue":"6","key":"pone.0255796.ref015","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-018242","article-title":"Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C)","volume":"146","author":"CA Rostad","year":"2020","journal-title":"Pediatrics"},{"key":"pone.0255796.ref016","first-page":"565","volume-title":"Cellular and molecular immunology","author":"AK Abbas","year":"2018","edition":"9"},{"key":"pone.0255796.ref017","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"G Vidarsson","year":"2014","journal-title":"Front Immunol"},{"issue":"12","key":"pone.0255796.ref018","doi-asserted-by":"crossref","first-page":"e1008064","DOI":"10.1371\/journal.ppat.1008064","article-title":"IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody","volume":"15","author":"SI Richardson","year":"2019","journal-title":"PLoS Pathog"},{"issue":"1","key":"pone.0255796.ref019","doi-asserted-by":"crossref","DOI":"10.3390\/v12010075","article-title":"Envelope-Specific IgG3 and IgG1 Responses Are Associated with Clearance of Acute Hepatitis C Virus Infection","volume":"12","author":"MR Walker","year":"2020","journal-title":"Viruses"},{"issue":"8","key":"pone.0255796.ref020","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/cid\/ciaa418","article-title":"Asymptomatic and Presymptomatic Infectors: Hidden Sources of Coronavirus Disease 2019 (COVID-19)","volume":"71","author":"G Li","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"9","key":"pone.0255796.ref021","doi-asserted-by":"crossref","first-page":"e0239250","DOI":"10.1371\/journal.pone.0239250","article-title":"Clinical characteristics and risk factors for coronavirus disease 2019 (COVID-19) among patients under investigation in Thailand","volume":"15","author":"J Bruminhent","year":"2020","journal-title":"PLoS One"},{"issue":"5","key":"pone.0255796.ref022","doi-asserted-by":"crossref","first-page":"e0006477","DOI":"10.1371\/journal.pntd.0006477","article-title":"Causes of acute undifferentiated fever and the utility of biomarkers in Chiangrai, northern Thailand","volume":"12","author":"T Wangrangsimakul","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"pone.0255796.ref023","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.4269\/ajtmh.20-0551","article-title":"Temporal Change of SARS-CoV-2 in Clinical Specimens of COVID-19 Pneumonia Patients","volume":"103","author":"V Luvira","year":"2020","journal-title":"Am J Trop Med Hyg"},{"issue":"6","key":"pone.0255796.ref024","doi-asserted-by":"crossref","first-page":"783 e1","DOI":"10.1016\/j.cmi.2019.10.032","article-title":"Longitudinal profiling of plasma cytokines in melioidosis and their association with mortality: a prospective cohort study","volume":"26","author":"T Kaewarpai","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"pone.0255796.ref025","doi-asserted-by":"crossref","first-page":"622","DOI":"10.4269\/ajtmh.18-0407","article-title":"Etiologies of Acute Undifferentiated Febrile Illness in Bangkok, Thailand","volume":"100","author":"V Luvira","year":"2019","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"pone.0255796.ref026","first-page":"69","article-title":"Statistics corner: A guide to appropriate use of correlation coefficient in medical research","volume":"24","author":"MM Mukaka","year":"2012","journal-title":"Malawi Med J"},{"issue":"52","key":"pone.0255796.ref027","article-title":"Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients","volume":"5","author":"AS Iyer","year":"2020","journal-title":"Sci Immunol"},{"issue":"52","key":"pone.0255796.ref028","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abe5511","article-title":"Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients","volume":"5","author":"B Isho","year":"2020","journal-title":"Sci Immunol."},{"key":"pone.0255796.ref029","doi-asserted-by":"crossref","first-page":"114025","DOI":"10.1016\/j.jviromet.2020.114025","article-title":"Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay","volume":"288","author":"J Marien","year":"2021","journal-title":"J Virol Methods"},{"key":"pone.0255796.ref030","article-title":"Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study","author":"S Weis","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"pone.0255796.ref031","doi-asserted-by":"crossref","first-page":"e0240502","DOI":"10.1371\/journal.pone.0240502","article-title":"Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019","volume":"15","author":"E Kowitdamrong","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"pone.0255796.ref032","article-title":"Comorbidities in SARS-CoV-2 Patients: a Systematic Review and Meta-Analysis","volume":"12","author":"WH Ng","year":"2021","journal-title":"mBio"},{"issue":"10","key":"pone.0255796.ref033","doi-asserted-by":"crossref","first-page":"e0241104","DOI":"10.1371\/journal.pone.0241104","article-title":"Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders","volume":"15","author":"E Marklund","year":"2020","journal-title":"PLoS One"},{"issue":"11","key":"pone.0255796.ref034","doi-asserted-by":"crossref","first-page":"e0242655","DOI":"10.1371\/journal.pone.0242655","article-title":"Antibody profiling and prevalence in US patients during the SARS-CoV2 pandemic.","volume":"15","author":"HK Krishnamurthy","year":"2020","journal-title":"PLoS One"},{"key":"pone.0255796.ref035","first-page":"2021.06.21.21258528","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","author":"S Feng","year":"2021","journal-title":"medRxiv"},{"issue":"19","key":"pone.0255796.ref036","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine","volume":"384","author":"J Sadoff","year":"2021","journal-title":"N Engl J Med"},{"issue":"10275","key":"pone.0255796.ref037","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"DY Logunov","year":"2021","journal-title":"The Lancet"},{"key":"pone.0255796.ref038","article-title":"BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers","author":"Y Lustig","year":"2021","journal-title":"Lancet Respir Med"},{"key":"pone.0255796.ref039","doi-asserted-by":"crossref","first-page":"100150","DOI":"10.1016\/j.lanepe.2021.100150","article-title":"Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel","volume":"7","author":"G Regev-Yochay","year":"2021","journal-title":"Lancet Reg Health Eur"},{"issue":"600","key":"pone.0255796.ref040","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abi9915","article-title":"Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection","volume":"13","author":"AJ Greaney","year":"2021","journal-title":"Sci Transl Med"},{"key":"pone.0255796.ref041","article-title":"Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers","author":"A Bayram","year":"2021","journal-title":"J Med Virol"},{"issue":"1","key":"pone.0255796.ref042","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"S Xia","year":"2021","journal-title":"Lancet Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0255796","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:34:49Z","timestamp":1628616889000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0255796"}},"subtitle":[],"editor":[{"given":"Aftab A.","family":"Ansari","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,8,10]]},"references-count":42,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0255796","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,10]]}}}